Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3167-3172

  Jhaveri, Faiyaaz M ^a   Klein, Eric A ^a   Kupelian, Patrick A ^a   Zippe, Craig ^a   Levin, Howard S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

EID: 0032885643     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3167     Document Type: Article

References (38)

1. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151:1283-1290, 1994
2. Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA 270:948-954, 1993
3. Mettlin C, Murphy GP, Lee F, et al: Characteristics of prostate cancers detected in a multimodality early detection program. Cancer 72:1701-1708, 1993
4. Carter HB, Pearson JD, Metter JE, et al: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992
5. Helzlsouer KJ, Newby J, Comstock GW: Prostate-specific antigen levels and subsequent prostate cancer: Potential for screening. Cancer Epidemiol Biomarkers Prev 1:537-540, 1992
6. Stenman UH, Hakama M, Knekt P, et al: Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344:1594-1598, 1994
7. Gann PH, Hennekens CH, Stampher MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 273:289-294, 1995
8. Tibblin G, Welin L, Bergstrom R, et al: The value of prostate specific antigen in early diagnosis of prostate cancer: The study of men born in 1913. J Urol 154:1386-1389, 1995
9. Stamey TA, Donaldson AN, Yemoto CE, et al: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes. J Urol 160:2412-2417, 1-24, 1998
10. Stephenson RA, Smart CR, James BC, et al: The fall in incidence of prostate carcinoma: On the down side of a prostate specific antigen induced peak in incidence - Data from the Utah Cancer Registry. Cancer 77:1342-1348, 1995
11. Soh S, Kattan MW, Berkman S, et al: Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 157:2212-2218, 1997
12. Stephenson RA: Population-based prostate cancer trends in the PSA era: Data from the SEER program. Monogr Urol 19:1-24, 1998
13. Epstein JI, Partin AW, Sanregeot J, et al: Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20:286-292, 1996
14. Pound CR, Partin AW, Epstein JI, et al: Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am 24:395-406, 1997
15. Kupelian P, Katcher J, Levin H, et al: Correlation of clinical and pathologic factors with rising PSA profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48:249-260, 1996
16. Partin AW, Pound CR, Clemens JQ, et al: Prostate-specific antigen after anatomic radical prostatectomy: The John Hopkins experience after ten years. Urol Clin North Am 20:713-725, 1993
17. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837-1842, 1994
18. Ohori M, Goad JR, Wheeler TM, et al: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 153:1160-1163, 1994
19. Zinke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152:1850-1857, 1994
20. Hall GS, Kramer CE, Epstein JI: Evaluation of radical prostatectomy specimens: A comparative analysis of various sampling methods. Am J Surg Pathol 16:315-324, 1992
21. Fleming ID, Cooper JS, Hensen DE, et al (eds): AJCC Cancer Staging Handbook (ed 4). Philadelphia, PA, Lippincott-Raven, 1992
22. Klein EA: Early continence after radical prostatectomy. J Urol 148:92-94, 1992
23. Klein E, Kupelian P, Tuason L, et al: Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. Urology 51:766-773, 1998
24. Hollander M, Wolfe DA: The one-way layout, in Nonparametric Statistical Methods. New York, NY, Wiley, 1973, pp 120-123
25. Mettlin C, Murphy GP, Babaian RJ, et al: The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 77:150-159, 1996
26. Murphy GP, Natarajan N, Pontes JE, et al: The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 127:928-934, 1982
27. Thompson IM, Ernst JJ, Gangai MP, et al: Adenocarcinoma of the prostate: Results of routine urological screening. J Urol 32:690-694, 1984
28. Ercole CJ, Lange PH, Mathiesen M, et al: Prostate-specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostate cancer. J Urol 138:1181-1184, 1987
29. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987
30. Oesterling JE, Chan DW, Epstein JI, et al: Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 139:766-772, 1988
31. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161, 1991
32. Partin AW, Yoo JK, Carter HB, et al: The use of prostate-specific antigen clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993
33. Ohori M, Wheeler TM, Kattan MW, et al: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154:1818-1824, 1995
34. Epstein JI: Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am 23:651-663, 1996
35. Klein EA, Kupelian P, Zippe C, et al: Identification of margin negative patients at risk for tumor recurrence after radical prostatectomy. J Urol 157:388, 1997 (abstr)
36. Humphrey PA, Walther PJ, Currin SM, et al: Histologic grade. DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostate carcinoma. Am J Surg Pathol 15:1165-1170, 1991
37. Kleer E, Larson-Keller JJ, Zinke H, et al: Ability of pre-operative serum prostate-specific antigen value to predict pathological stage and DNA ploidy. Urology 150:396-398, 1993
38. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451, 1997